Skip to main content
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Clin Cancer Res. 2012 Jul 12;18(18):5081–5089. doi: 10.1158/1078-0432.CCR-12-0078

Table 4B.

Free versus bound aflibercept concentrations

Dose (mg/kg) Cycle Aflibercept concentrations (ng/ml) Free/Bound
Free Bound
2.0 Cycle 1, Day 8 (n=3) 6.86 (6.16–7.56) 2.50 (1.76–3.96) 3.87
Cycle 2, Pretreatment (n=4) 1.50 (0.12–3.43) 3.61 (2.05–6.22) 0.52
Cycle 5, Pretreatmnt (n=3) 4.20 (1.81–8.01) 8.16 (4.47–13.20) 0.43
2.5 Cycle 1, Day 8 (n=5) 4.96 (3.33–6.02) 2.39 (2.06–2.69) 2.10
Cycle 2, Pretreatment (n=5) 1.45 (0.99–2.01) 3.35 0.44
Cycle 5, Pretreatment (n=1) 0.49 4.34 0.11
3.0 Cycle 1, Day 8 (n=4) 7.46 (4.59–9.94) 1.96 (1.78–2.21) 3.88
Cycle 2, Pretreatment (n=6) 2.20 (0.81–4.15) 3.27 (2.79–3.84) 0.71
Cycle 5, Pretreatment (n=0)

Values represent mean concentrations with range in parentheses.

*

NOTE: Cycle 1, Day 8- N=3, Cycle 2 Pretreatment- N=5 One patient had bound measurements at each time point, but free measurements only for the Cycle 5, pretreatment timepoint.